In addition to being the first line of defense against pathogenic attack, the immune system seeks out aberrant cells within the body that may become cancerous. In response, precancerous and cancerous cells may exploit immune checkpoint pathways to evade immune detection and destruction. In order to block these tumorigenic cells, novel therapeutics that modulate immune checkpoint signaling have been developed, with some already available and others in clinical trials. Further development of effective therapeutics for use in personalized medicine requires the identification and characterization of a diverse range of immune checkpoint biomarkers. This webinar will explore recent progress and future directions in translational and clinical efforts centered on checkpoint modulators and combination therapies matched to the molecular profile of individual tumors and the genetic background of patients.
During the webinar, the speakers will discuss:
- The use of immune checkpoint blockades to treat malignancies and reverse T-cell exhaustion
- How to identify mechanistic biomarkers that could inform a combinatorial approach to therapy
- The ability of different therapy combinations to target the right immune cells.
This webinar will last for appoximately 60 minutes.